MacroGenics, Inc. (MGNX)
Market Cap | 462.80M |
Revenue (ttm) | 151.94M |
Net Income (ttm) | -119.76M |
Shares Out | 65.00M |
EPS (ttm) | -1.95 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 802,236 |
Open | 6.87 |
Previous Close | 6.69 |
Day's Range | 6.80 - 7.36 |
52-Week Range | 2.13 - 10.20 |
Beta | 1.95 |
Analysts | Buy |
Price Target | 10.61 (+49.02%) |
Earnings Date | May 2, 2023 |
About MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugat... [Read more]
Financial Performance
In 2022, MacroGenics's revenue was $151.94 million, an increase of 96.19% compared to the previous year's $77.45 million. Losses were -$119.76 million, -40.75% less than in 2021.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is $10.61, which is an increase of 49.02% from the latest price.
News

MacroGenics (MGNX) Surpasses Q4 Earnings Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of 170% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics Provides Corporate Update and 2022 Financial Results
ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

Synaffix Announces Expansion of ADC Collaboration with MacroGenics
MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix's linker-payload technologies Expanded collaboration incl...

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 73.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the po...

Buy These 3 Top Stocks for Solid Earnings Acceleration
Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & Euronav (EURN) at the moment for superb earnings acceleration.

MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Here's How to Find Cheap Stocks Under $10 to Buy for December
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

Wall Street Analysts Believe MacroGenics (MGNX) Could Rally 123%: Here's is How to Trade
The consensus price target hints at a 122.6% upside potential for MacroGenics (MGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

5 Best Stocks to Invest in for Solid Earnings Acceleration
Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & LivePerson (LPSN) at the moment for superb earnings acceleration.

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

Wall Street Analysts See a 279% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 278.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the p...

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut...

MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
FOSTER CITY, Calif.

Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 291% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the pos...

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?